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High-Density Lipoprotein Cholesterol
and the Risk of Cancer in Randomized
Controlled Trials of Lipid-Altering Therapy
Haseeb Jafri, MD,* Alawi A. Alsheikh-Ali, MD, MS,†‡ Richard H. Karas, MD, PHD*
Boston, Massachusetts; and Abu Dhabi, United Arab Emirates
Objectives We sought to examine the relationship between high-density lipoprotein cholesterol (HDL-C) levels and the risk
of the development of cancer in large randomized controlled trials (RCTs) of lipid-altering interventions.
Background Epidemiologic data demonstrate an inverse relationship between serum total cholesterol levels and incident can-
cer. We recently reported that lower levels of low-density lipoprotein cholesterol are associated with a signifi-
cantly higher risk of incident cancer in a meta-analysis of large RCTs of statin therapy. However, little is known
about the relationship between HDL-C levels and cancer risk.
Methods A systematic MEDLINE search identified lipid intervention RCTs with 1,000 person-years of follow-up, providing
baseline HDL-C levels and rates of incident cancer. Using random-effects meta-regressions, we evaluated the
relationship between baseline HDL-C and incident cancer in each RCT arm.
Results A total of 24 eligible RCTs were identified (28 pharmacologic intervention arms and 23 control arms), with
625,477 person-years of follow-up and 8,185 incident cancers. There was a significant inverse association be-
tween baseline HDL-C levels and the rate of incident cancer (p  0.018). The inverse association persisted after
adjusting for baseline low-density lipoprotein cholesterol, age, body mass index (BMI), diabetes, sex, and smok-
ing status, such that for every 10-mg/dl increment in HDL-C, there was a 36% (95% confidence interval: 24% to
47%) relatively lower rate of the development of cancer (p  0.001).
Conclusions There is a significant inverse association between HDL-C and the risk of incident cancer that is independent of
LDL-C, age, BMI, diabetes, sex, and smoking. (J Am Coll Cardiol 2010;55:2846–54) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.069t
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ahe relationship between serum cholesterol levels and the
isk of cancer in humans is an area of considerable research and
ebate, especially in the current era of intensive lipid-
odifying therapy and more aggressive cholesterol goals to
educe the risk of cardiovascular disease. To date, the literature
n cholesterol and cancer has focused predominantly on total
erum cholesterol, demonstrating an inverse relationship be-
ween serum cholesterol levels and incident cancer (1). More
ecently, we reported that serum levels of low-density lipopro-
ein cholesterol (LDL-C) are significantly and inversely related
rom the *Molecular Cardiology Research Institute, Department of Medicine, and
he †Institute for Clinical Research and Health Policy Studies, Tufts Medical Center
nd Tufts University School of Medicine, Boston, Massachusetts; and the ‡Institute
f Cardiac Sciences, Sheikh Khalifa Medical City, Abu Dhabi, United Arab
mirates. Dr. Alsheikh-Ali is a recipient of a faculty development award from
fizer/Tufts Medical Center. Dr. Karas has received speaker and consulting fees from
bbott Laboratories and Merck.t
Manuscript received October 1, 2009; revised manuscript received December 14,
009, accepted December 17, 2009.o the rates of incident cancer in large randomized controlled
rials (RCTs) of hydroxymethylglutaryl coenzyme A reductase
nhibitors (statins), such that lower levels of LDL-C are
ssociated with higher rates of incident cancer (2).
See page 2855
High-density lipoprotein cholesterol (HDL-C) contrib-
tes importantly to cardiovascular disease risk, independent
f the effects of LDL-C, with a significant inverse relation-
hip between HDL-C levels and the risk of cardiovascular
isease (3–7). However, very little is known about whether
here is a relationship between HDL-C levels and cancer
isk. Only a small number of studies have explored the
ssociation of HDL-C and cancer, and these have produced
ixed results (8–11). To date, there is no systematic
nalysis examining the relationship of HDL-C levels and
he risk of incident cancer. In the current study, we took
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June 22, 2010:2846–54 HDL-C and Cancer Riskdvantage of the numerous large-scale trials of lipid-
odifying therapy to examine the relationship between
DL-C levels and the risk of developing cancer.
ethods
rial inclusion. A MEDLINE search identified lipid
ntervention RCTs, published up to September 2009 in the
nglish literature, with at least 1,000 person-years of
ollow-up. To be eligible, trials had to report both baseline
DL-C and rates of incident cancer. The electronic search
trategy included the following terms: cancer, neoplasm,
DL-C, fibrate, niacin, hydroxymethylglutaryl coenzyme
reductase inhibitor, statin, lovastatin, pravastatin, sim-
astatin, atorvastatin, cerivastatin, fluvastatin, and rosuva-
tatin. Citations were limited using the terms “human,”
English language,” and “randomized controlled trial.” Ad-
itionally, a manual review of the reference lists of eligible
rials was performed to ensure that all appropriate studies
ere included.
ata extraction. All citations were screened at the abstract
evel. Full articles of eligible trials were independently
eviewed by 2 investigators (H.J. and A.A.A.-A.), and data
irectly extracted into electronic data tables. For each
ligible study, the following variables were extracted from
he published article: the intervention used and the dose; the
umber of patients in the intervention and control arms;
uration of follow-up; baseline and on-treatment serum
DL-C, LDL-C, total cholesterol, and triglyceride levels;
nd the number of patients with newly diagnosed cancer
uring the follow-up period. In addition, for each trial arm,
ge, sex, diabetes, smoking status, and body mass index
BMI) were recorded at baseline. Nonmelanoma skin can-
ers were not consistently recorded in all trials and were
herefore not included in the present analysis. Person-years
f follow-up for each study arm were calculated by multi-
lying the reported follow-up in years by the number of
ubjects in each arm. The number of incident cancers that
ere included in the analysis was taken from the values
eported as defined in each individual study. Cancer rates
ere expressed as number of incident cancers per 1,000
atient-years of follow-up for the study arm of interest.
rimary and secondary analyses. Our pre-specified pri-
ary analysis examined the association between baseline
DL-C levels and incident cancer risk. Each trial arm is
onsidered a separate observation, and intervention and
ontrol arms are included together in the analysis. We
reviously showed in a similar dataset that statin use is not
ssociated with cancer risk (2). The relationship between
aseline HDL-C levels and cancer risk was assessed using
andom-effects meta-regressions (see the Statistical meth-
ds section). Secondary analyses were performed examining
ny association between the rate of incident cancer and the
ollowing variables: baseline LDL-C, age, BMI, sex, and
he proportion of subjects who smoked or had diabetes. All
he variables that showed a significant univariate association aith incident cancer were used to
djust the meta-regression of in-
ident cancer risk and baseline-
DL-C in a multivariate model.
he above analyses were all repeated
sing on-treatment HDL-C in
lace of baseline HDL-C.
tatistical methods. In the main
nalyses, we assumed that inci-
ent cancer rates were normally
istributed. We used random-
ffects meta-regressions to evalu-
te the association between inci-
ent cancer and baseline HDL-C levels or the other variables
f interest, as described previously (12). We estimated
ultivariate associations controlling for each of the predic-
or variables that showed a significant univariate association
ith incident cancer. We fitted a single regression line to
he pooled data of both intervention and control cohorts
ndexed by a variable indicating cohort type (intervention vs.
ontrol). To determine whether the association of HDL-C
ith cancer differed between the intervention and control
rms, we tested the significance of the interaction term of
ohort type with baseline HDL-C level. We repeated this
nalysis for treatment type (statin, fibrate, other intervention
r control) to determine whether the association of HDL-C
nd cancer was significantly modified by treatment type.
ontinuous variables were compared using the Student t
est for independent or paired samples as appropriate. To
nsure that our findings were not sensitive to the assump-
ion of a normal distribution of cancer rates, these analyses
ere repeated, assuming that incident cancer rates follow a
oisson distribution. A p value 0.05 was considered statisti-
ally significant. All analyses were performed with STATA
ersion 9.2 (StataCorp, College Station, Texas).
esults
ligible trials. Our search yielded 2,300 citations that were
creened at the abstract level. A total of 2,250 abstracts were
xcluded (1,458 with follow-up of 1,000 person-years,
95 were not lipid intervention studies, and 497 were not
CTs), resulting in 50 full-text articles retrieved for detailed
valuation. Of these, 26 were eventually excluded (20 had
1,000 person-years of follow-up, 5 did not report cancer
ncidence [13–17], and 1 did not report baseline HDL-C
18]). Hence, a total of 24 lipid intervention RCTs were
ncluded in the main analysis (28 pharmacologic interven-
ion arms and 23 control arms) (Table 1) (19–42). There
as a total of 76,265 patients allocated to the lipid inter-
ention arms and 69,478 patients allocated to the control
rms. The median duration of follow-up was 5 years
interquartile range [IQR] 2.7 to 5.2 years). The cumulative
xposure was 319,062 person-years in the lipid intervention
Abbreviations
and Acronyms
BMI  body mass index
CI  confidence interval
HDL-C  high-density
lipoprotein cholesterol
IQR  interquartile range
LDL-C  low-density
lipoprotein cholesterol
RCT  randomized
controlled trialrms and 306,415 person-years in the control arms. A total
Characteristics of Large Randomized Controlled Trials Included in the Present AnalysisTable 1 Characteristics of Large Randomized Controlled Trials Included in the Present Analysis
Study (Ref. #), Year Arm Dose* N
Follow-Up,
yrs
Incident
Cancer
Baseline
HDL-C,
mg/dl
Baseline
LDL-C,
mg/dl
Age,
yrs
BMI,
kg/m2 Diabetes, %
Sex,
% Male Smokers, % Cancer Site (Primary)
LRC-CPPT (19), 1984 Cholestyramine 24 g 1,906 7.4 57 44.4 205 47.6 26.4 0 100 38 NR
Placebo 1,900 57 44.4 205 47.7 26.2 0 100 37 NR
HHS (20), 1987 Gemfibrozil 600 mg BID 2,051 5 31 47.1 189.2 47 26.6 2.4 100 36.5 NR
Placebo 2,030 26 47.6 188.2 47 26.6 2.9 100 35.8 NR
POSCH (21), 1990 Ileal bypass NA 421 9.7 32 40 179 51 NR 0 90.7 35 NR
Control 417 28 40 179 51 NR 0 90.7 35 NR
EXCEL (22), 1991 Lovastatin 20 mg 1,653 1 18 45 180 56 26 0 60 18 NR
Lovastatin 40 mg 1,653 20 45 180 56 26 0 58 18 NR
Lovastatin 20 mg BID 1,653 8 45 180 56 26 0 59 18 NR
Lovastatin 40 mg BID 1,653 18 45 180 56 26 0 58 18 NR
Placebo 1,653 12 45 180 56 26 0 58 18 NR
4S (23), 1994 Simvastatin 40 mg 2,221 5.4 90 45.5 188 59 26 5 82 24 GI 12
Placebo 2,223 96 45.9 188 59 26 4 81 27 GI 14
WOSCOPS (24), 1995 Pravastatin 40 mg 3,302 5.0 116 44 192 55 26 41 100 44 GU 32, GI 31, respiratory 27, other 26
Placebo 3,293 106 44 192 55 26 35 100 44 GU 26, GI 30, respiratory 28, other 22
CARE (25) 1996 Pravastatin 40 mg 2,081 5.0 172 39 139 59 28 14 86 21 GI 26, breast 12, hematological 8, melanoma 4
Placebo 2,078 161 39 139 59 28 15 86 21 GI 37, breast 1, hematological 10
Post-CABG (26), 1997 Lovastatin 40–80 mg 676 4.3 48 39.1 155.4 48 NR 2.8 92 62 NR
Lovastatin 2.5–5 mg 675 42 39.4 155.6 42 NR 2.4 93 61 NR
AFCAPS/TexCAPS (27), 1998 Lovastatin 40 mg 3,304 5.2 252 36.6 150 58 27 6.8 85 13 Prostate 109, colon 25, lung 22, melanoma 14,
breast 13, lymphoma 12, bladder 12
Placebo 3,301 259 36.6 150 58 27 5.4 85 12 Prostate 108, colon 20, lung 17, melanoma 27,
breast 9, lymphoma 11, bladder 11
LIPID (28), 1998 Pravastatin 40 mg 4,512 6.1 379 36 150 62 NR 9 83 9 Breast 10, no other sites reported
Placebo 4,502 399 36 150 62 NR 9 83 10 Breast 10, no other sites reported
VA-HIT (29), 1999 Gemfibrozil 600 mg BID 1,264 5.1 124 32 111 64 29 24 100 22 Prostate 55, GI 18, lung 20, GU 11,
hematologic 6, head and neck 5,
melanoma 1, other 15
Placebo 1,267 129 32 112 64 29 25 100 19 Prostate 37, GI 25, lung 24, GU 17,
hematologic 11, head and neck 8,
melanoma 9, other 8
BIP (30), 2000 Benzafibrate 400 mg 1,542 6.2 85 34.6 149 60 26.7 10 91.2 11.4 NR
Placebo 1,548 91 34.6 148 60 26.7 10 91.6 12.1 NR
GISSI (31), 2000 Pravastatin 20 mg 2,138 1.9 16 45.7 151.8 60 26 12.9 87 12 NR
Placebo 2,133 25 45.7 151.5 60 27 14.4 86 11 NR
KLIS (32), 2000 Pravastatin 10–20 mg 2,219 5.0 77 48.9 169 58 24 21.8 100 38 NR
Conventional therapy 1,634 55 49.7 160 58 24 24.4 100 41 NR
ALLHAT-LLT (33), 2002 Pravastatin 40 mg 5,170 4.8 378 47.6 145.6 66 30 35.9 51 23 Lung 63, colon 46, breast 34
Placebo 5,185 369 47.4 145.5 66 30 34.4 51 23 Lung 78, colon 38, breast 37
Continued on next page
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ContinuedTable 1 Continued
Study (Ref. #), Year Arm Dose* N
Follow-Up,
yrs
Incident
Cancer
Baseline
HDL-C,
mg/dl
Baseline
LDL-C,
mg/dl
Age,
yrs
BMI,
kg/m2 Diabetes, %
Sex,
% Male Smokers, % Cancer Site (Primary)
HPS (34), 2002 Simvastatin 40 mg 10,269 5.0 814 40.9 131.2 63 NR 19.5 75 14 GU 259, GI 228, respiratory 179,
hematologic 64, connective
tissue 60, CNS 12, other 6,
not specified 38
Placebo 10,267 803 40.9 131.2 63 NR 19.2 75 14 GU 272, GI 223, respiratory 167,
hematologic 52, connective
tissue 68, CNS 68, other 2,
not specified 49
LIPS (35), 2002 Fluvastatin 80 mg 844 3.9 46 38 131 60 27 14.2 84 25 NR
Placebo 833 49 37 132 60 26 9.8 83 28 NR
PROSPER (36), 2002 Pravastatin 40 mg 2,891 3.2 245 50.2 146.7 75 27 10.5 48 26 GI 65, GU 58, respiratory 46,
breast 18, other 58
Placebo 2,913 199 50.2 146.7 75 27 11 48 26 GI 45, GU 59, respiratory 42,
breast 11, other 42
4D (37), 2005 Atorvastatin 20 mg 619 2.25 44 36 125 65.7 27.6 100 53.8 8.1 NR
Placebo 636 39 36 127 65.7 27.5 100 54.1 9.1 NR
FIELD (38), 2005 Fenofibrate 20 mg 4,895 5.0 393 42.5 118.5 62 29.8 100 63 9 GI 114, prostate 65, respiratory 45,
breast 37, GU 24
Placebo 4,900 373 42.5 118.5 62 29.8 100 63 9 GI 109, prostate 59, respiratory 41,
breast 38, GU 31
MEGA (39), 2006 Pravastatin 20 mg 3,866 5.3 126 57.5 156.3 58 24 21 32 21 GI 58, respiratory 10, breast 10,
GU 14, other 30
Diet 3,966 119 57.5 156.3 58 24 21 31 20 GI 65, respiratory 13, breast 15,
GU 10, other 30
CORONA (40), 2007 Rosuvastatin 10 mg 2,497 2.7 156 48 136.9 73 27 30 76 9 NR
Placebo 2,514 144 47.6 136 73 27 29 76 8 NR
JUPITER (41), 2008 Rosuvastatin 20 mg 8,901 1.9 298 49 108 66 28.3 0 61.5 15.7 NR
Placebo 8,901 314 49 108 66 28.4 0 62.1 16 NR
AURORA (42), 2009 Rosuvastatin 10 mg 1,389 3.8 107 45 99 64.1 25.4 27.9 61.3 14.5 NR
Placebo 1,384 118 45 100 64.3 25.4 24.8 63 16.4 NR
*Target dose is in milligrams per day. Year refers to year of publication. All lipid levels are mean or median levels as reported in the trial. Age is the mean or median age for the arm reported in the trial.
AFCAPS/TexCAPS  Air Force/Texas Coronary Atherosclerosis Prevention Study; ALLHAT-LLT  Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; AURORA  A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis:
An Assessment of Survival and Cardiovascular Events; BID twice daily; BIP Bezafibrate Infarction Prevention Study; BMI bodymass index; CARE Cholesterol and Recurrent Events trial; CNS central nervous system; CORONA Controlled Rosuvastatin in Multinational
Trial in Heart Failure; EXCEL  Expanded Clinical Evaluation of Lovastatin; FIELD  Fenofibrate Intervention and Event Lowering in Diabetes; GI  gastrointestinal; GISSI  Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico; GU  genitourinary; HHS 
Helsinki Heart Study; HPS Heart Protection Study; HDL-C high-density lipoprotein cholesterol; JUPITER Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; KLIS Kyushu Lipid Intervention Study; LDL-C low-density lipoprotein
cholesterol; LIPID  Long-Term Intervention With Pravastatin in Ischemic Disease study; LIPS  Lescol Intervention Prevention Study; LRC-CPPT  Lipid Research Clinics Coronary Primary Prevention Trial; MEGA  Management of Elevated Cholesterol in the Primary
Prevention Group of Adult Japanese study; NA  not available; NR  not reported; POSCH  Program on the Surgical Control of the Hyperlipidemias; Post-CABG  Post Coronary Artery Bypass Graft trial; PROSPER  Prospective Study of Pravastatin in the Elderly at Risk;
VA-HIT  Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial; WOSCOPS  West of Scotland Coronary Prevention Study; 4S  Scandinavian Simvastatin Survival Study.
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HDL-C and Cancer Risk June 22, 2010:2846–54f 8,185 patients with incident cancer were included. The
ncidence of newly diagnosed cancer ranged from 3.0 to
1.6 per 1,000 person-years in the lipid intervention arms
nd from 2.6 to 27.3 per 1,000 person-years in the control
rms.
Among all the eligible RCTs, there was a wide range of
aseline and on-treatment lipid parameters, with compara-
le baseline levels in the intervention versus control arms
nd favorable on-treatment changes in the intervention
rms (Table 1). The median baseline HDL-C for all arms
ncluded was 44.4 mg/dl (IQR 39.0 to 47.4 mg/dl). In the
ipid-intervention arms, median baseline and on-treatment
DL-C levels were 44.7 mg/dl (IQR 39.0 to 46.7 mg/dl)
nd 46.4 mg/dl (IQR 42.1 to 49.2 mg/dl), respectively (p
.001). Baseline and on-treatment HDL-C levels did not
iffer in the control arms.
nivariate meta-regressions. PRIMARY ANALYSIS. In uni-
ariate random-effects meta-regression analysis, there was a
ignificant inverse relationship between baseline HDL-C
evel and the rate of incident cancer, such that every
0-mg/dl increment in HDL-C was associated with a 28%
95% confidence interval [CI]: 5% to 45%) relatively lower
ancer rate (p  0.018) (Fig. 1). The significant inverse
ssociation between baseline HDL-C and incident cancer
id not differ between the intervention and the control arms
p 0.95) and was not modified by the type of intervention
sed (p  0.726).
ECONDARY ANALYSIS. When evaluating the other inde-
endent variables in the study, there was a significant
nverse relationship between baseline LDL-C level and the
ate of incident cancer, such that every 10-mg/dl decrement
n LDL-C was associated with a 15% (95% CI: 12% to
Figure 1 Baseline Levels of HDL-C (mg/dl) and Rate of Inciden
The size of each circle represents the relative size (i.e., the weight of the arm) of
The solid black line is the combined weighted regression line for all trial arms inc8%) relatively higher cancer rate (p  0.001) (Fig. 2). In
ddition, there was a significant and direct relationship
etween both age and BMI and the rate of incident cancer,
uch that every 5-year increment in age was associated with
33% (95% CI: 22% to 45%) relatively higher cancer rate
nd every 1-kg/m2 increment in BMI was associated with a
1% (95% CI: 8% to 35%) relatively higher cancer rate (p 
.001 and p  0.001, respectively) (Figs. 3 and 4). Addi-
ionally, sex, the proportion of smokers, and the proportion
f patients with diabetes mellitus were significantly associ-
ted with incident cancer (p  0.01 for all univariate
ssociations).
ultivariate meta-regressions. Multivariate random-
ffects meta-regression analyses were conducted for baseline
DL-C and incident cancer, controlling for the variables
hat had significant independent associations with incident
ancer in the univariate regression models. After adjusting
or baseline LDL-C, age, BMI, diabetes, sex, and smoking
tatus, the significant inverse relationship between baseline
DL-C and rate of incident cancer persisted, such that for
very 10-mg/dl increase in HDL-C, there was a 36% (95%
I: 24% to 47%; p  0.001) relatively lower rate of incident
ancer. In the multivariate model including all relevant
ariables in addition to HDL-C, LDL-C and sex (percent-
ge of males) continued to have a significant inverse
elationship with the rate of incident cancer (p  0.02 and
 0.007, respectively), and age continued to have a
ignificant direct relationship with rate of incident cancer
p  0.001). In this multivariable model, however, the
irect relationship between smoking status and rate of
ncident cancer approached significance, but failed to
chieve it (p  0.06), and the relationships between both
cer per 1,000 Person-Years
rial arm for the lipid intervention arm (black) and the control arm (red).
in the analysis. p  0.018. HDL-C  high-density lipoprotein cholesterol.t Can
each t
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June 22, 2010:2846–54 HDL-C and Cancer RiskMI and diabetes status with incident cancer rate were no
onger statistically significant (p  0.71 and p  0.78,
espectively). All findings were unchanged when the anal-
ses were repeated using on-treatment instead of baseline
DL-C levels or with Poisson meta-regressions (data not
hown).
iscussion
he current analysis demonstrates a significant inverse
ssociation between baseline HDL-C levels and the risk of
Figure 2 Baseline Levels of LDL-C (mg/dl) and Rate of Inciden
The size of each circle represents the relative size (i.e., the weight of the arm) of
The solid black line is the combined weighted regression line for all trial arms inc
Figure 3 Age (in Years) and Rate of Incident Cancer per 1,000
The size of each circle represents the relative size (i.e., the weight of the arm) of
The solid black line is the combined weighted regression line for all trial arms inceveloping cancer in large RCTs of lipid-altering therapy.
mportantly, this relationship persisted after controlling for
otentially confounding variables, including baseline levels
f LDL-C, age, BMI, and smoking status.
The present study is the most comprehensive assessment
f the relationship between HDL-C and risk of cancer to
ate. This study builds on the few previous nested case-
ontrol studies of HDL-C and risk of cancer. Studies from
he breast cancer literature provide mixed results. Moorman
t al. (8), in an analysis of 95,000 women from the Kaiser
cer per 1,000 Person-Years
rial arm for the lipid intervention arm (black) and the control arm (red).
in the analysis. p  0.001. LDL-C  low-density lipoprotein cholesterol.
on-Years
rial arm for the lipid intervention arm (black) and the control arm (red).
in the analysis. p  0.001.t Can
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HDL-C and Cancer Risk June 22, 2010:2846–54ermanente Medical Care Program and Kucharska-
ewton et al. (9) in a study of 7,575 women from the ARIC
Atherosclerosis Risk in Communities) study suggested that
he relationship of HDL-C and breast cancer varies by
enopausal status, where an inverse association between
DL-C and breast cancer exists in pre-menopausal
omen, but not in post-menopausal women. In contrast, a
tudy of 38,823 Norwegian women by Furberg et al. (10)
uggested that low levels of serum HDL-C are indepen-
ently associated with increased breast cancer risk in post-
enopausal females. Additionally, a recent analysis of the
TBC (Alpha-Tocopherol Beta-Carotene Cancer Preven-
ion) study, examining 29,093 Finnish male smokers, iden-
ified a significant inverse relationship between HDL-C
evels and the risk of incident cancer. They found that this
ignificant inverse association, largely attributed to cancers
f the lung, prostate, liver, and hematopoietic system,
ersisted after exclusion of cases diagnosed during the first
2 years of follow-up (11). These previous analyses are
imited by sex or cancer type studied, whereas the current
tudy included a mixed population and reported a broad
ariety of cancers.
As with all association studies, the present study should
ot be interpreted as implying a causal relationship between
ow HDL-C levels and cancer risk. However, it is interest-
ng to consider potential biological mechanisms for the
bserved inverse association between HDL-C and incident
ancer risk. The primary mechanism by which HDL-C
xerts its atheroprotective effects is via reverse cholesterol
ransport, but HDL-C has also been shown to have other
eneficial effects via its anti-inflammatory and antioxidant
roperties (7,43–51). Cancer is well-known to be a proin-
Figure 4 BMI (kg/m2) and Rate of Incident Cancer per 1,000
The size of each circle represents the relative size (i.e., the weight of the arm) of
The solid black line is the combined weighted regression line for all trial arms incammatory state, in which inflammatory cells actively par- (icipate in the neoplastic process, allowing tumor cell
roliferation, survival, and migration (52–54). Therefore, it
s plausible that HDL-C, by mechanisms that are not yet
nown, may influence some of the proinflammatory medi-
tors involved in carcinogenesis. Further work will need to
e done to elucidate these potential mechanisms.
As a secondary analysis, we examined the other potential
ariables associated with cancer risk in our dataset. We
onfirmed our previous report that LDL-C levels are
nversely associated with the risk of incident cancer in a
imilar database (2). Additionally, the current analysis
urther supports the well-established association of age and
isk of cancer. Furthermore, we demonstrated that in
nivariate analyses, there was an association between BMI
nd cancer; however, this relationship was no longer signif-
cant after adjusting for HDL-C. The univariate association
etween BMI and incident cancer reported here is consis-
ent with a recent meta-analysis of prospective observational
tudies by Renehan et al. (55), although they did not adjust
or HDL-C.
tudy limitations. Our findings are limited by the use of
rial-level data. It is possible that the relationship of
DL-C and cancer could reflect differences in study design
hat relate to HDL-C at the population level, thus con-
ounding our observed association between HDL-C levels
nd cancer. Access to individual patient data would allow a
ore robust analysis. Furthermore, the process for the
dentification of cancers was not specifically reported, nor
as it uniform across all RCTs, and, thus, an effect of
ifferences in the definitions of cancers could not be
xcluded. Also, many of the recent, large-scale lipid-
owering RCTs did not report newly diagnosed cancer
n-Years
rial arm for the lipid intervention arm (black) and the control arm (red).
in the analysis. p  0.001. BMI  body mass index.Perso
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June 22, 2010:2846–54 HDL-C and Cancer Riskncluded. Although the possibility of reverse causality could
ot be addressed in the current analysis because we did not
ave access to the individual patient data and could not
etermine the exact time of cancer diagnosis, it seems
nlikely that cancer-associated reductions in HDL-C levels
n the small subgroup of these cohorts in which cancer
ctually developed would significantly affect the mean base-
ine levels for the large cohort overall. Finally, given the
edian follow-up time of 5 years, we may not have been
ble to fully appreciate whether the inverse relationship
etween HDL-C and incident cancer risk is altered over
onger periods of follow-up.
onclusions
verall, the current epidemiologic data demonstrate an inverse
elationship between serum total cholesterol levels and rate of
ncident cancer. We recently showed in a meta-analysis that
here is a strong inverse relationship between LDL-C and the
ate of incident cancer. The current study, based on a system-
tic analysis, is the first to report a strong and significant inverse
elationship between baseline HDL-C and the rate of incident
ancer. These findings underscore the importance of reporting
ancer rates in future lipid intervention trials and further
upport the importance of basic scientific research to determine
otential underlying mechanisms that might mediate these
ssociations.
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